---
title: "Replimune Group FY 2026: Revenue $0 Net loss $(313.9) M — 10-K Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291144155.md"
description: "Replimune Group reported a net loss of $313.94 million for FY 2026, up from $247.30 million in FY 2025, with zero product revenue. The company increased R&D spending by 17% to advance programs RP1-3 and support clinical trials IGNYTE-3 and REVEAL. Commercial infrastructure was built for a potential RP1 launch. Management expects cash reserves to fund operations through Q1 2027."
datetime: "2026-06-29T12:15:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291144155.md)
  - [en](https://longbridge.com/en/news/291144155.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291144155.md)
generator: "portal-rs"
---

# Replimune Group FY 2026: Revenue $0 Net loss $(313.9) M — 10-K Summary

Replimune Group, Inc. reported a net loss of $(313.94) M for the fiscal year ended March 31, 2026, compared with a $(247.30) M net loss in fiscal 2025, as the company recorded no product revenue while investing in research, development and commercial readiness — 10-K Summary.

**Financial Highlights**

-   Revenue: $0 for FY 2026 and $0 for FY 2025 (no product revenue; no approved products).
-   Net income: $(313.94) M net loss for FY ended Mar 31, 2026, versus $(247.30) M net loss in FY 2025; loss increased by (27%).
-   Diluted EPS: Not disclosed as a consolidated diluted EPS figure in the MD&A only consolidated net loss amounts provided.

**Business Highlights**

-   R&D expansion: Research and development spending increased about 17% year over year to advance lead programs RP1, RP2 and RP3 and to support the IGNYTE‑3 and REVEAL trials.
-   Clinical progress: Enrollment ramped for the IGNYTE‑3 confirmatory study and the REVEAL trial; CERPASS and certain cohorts were wound down.
-   Commercial readiness: The company built pre‑launch commercial infrastructure and increased headcount in preparation for a potential RP1 launch.
-   Liquidity outlook: Management expects cash to fund operations through Q1 2027 under the current plan, focusing near term on the FDA pathway and program prioritization.

Original SEC Filing: Replimune Group, Inc. \[ REPL \] - 10-K - Jun. 29, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [REPL.US](https://longbridge.com/en/quote/REPL.US.md)

## Related News & Research

- [Replimune management to present fireside chat at Cantor Global Healthcare Conference](https://longbridge.com/en/news/297910099.md)
- [Replimune FY27 Q1 net loss narrows to $69.8 million; R&D expenses fall to $49.3 million](https://longbridge.com/en/news/295931365.md)
- [REG - Net Zero Infrastrctr - Allotment and Admission of New Shares](https://longbridge.com/en/news/298192415.md)
- [IOT: Q2 FY27 ARR grew 30% to $2.1B, with raised FY27 revenue guidance and improved margins](https://longbridge.com/en/news/297955529.md)
- [Penguin Solutions (PENG) AI Infra Summit Spotlight Puts Valuation Back In Focus](https://longbridge.com/en/news/297990404.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**